Cardio Diagnostics Holdings (NASDAQ: CDIO), an artificial intelligence-driven precision cardiovascular medicine company, has released a whitepaper examining the diagnostic challenges associated with non-obstructive coronary artery disease (NOCAD), a condition in which patients experience symptoms of coronary disease without significant blockages in major coronary arteries. The announcement, detailed in a press release, underscores a critical gap in current diagnostic approaches that could affect millions of Americans.
The whitepaper focuses on the limitations of invasive coronary angiography, which evaluates coronary anatomy rather than function. This distinction is crucial because many patients with NOCAD may have normal or non-obstructive coronary arteries on angiography yet still experience angina and other symptoms. The report highlights ischemia with no obstructive coronary arteries (INOCA), a condition affecting an estimated 3 million to 4 million Americans. INOCA is often underdiagnosed because traditional testing fails to identify functional abnormalities in the coronary microcirculation.
According to the whitepaper, NOCAD encompasses several subgroups, including INOCA, and diagnostic pathways need to be optimized to identify patients earlier. The report outlines clinical approaches that could improve detection, including the potential role of epigenetics-based testing in primary care. Epigenetic testing examines changes in gene expression that do not involve alterations to the DNA sequence, offering a non-invasive way to assess cardiovascular risk and disease presence. By integrating such testing into routine care, clinicians might be able to flag coronary disease that conventional angiography would miss.
Cardio Diagnostics also highlighted its ongoing efforts to build clinical evidence supporting PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease. The test could have potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing. The company's proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine (Core Technology) powers PrecisionCHD, aiming to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.
This news matters because NOCAD and INOCA represent a significant unmet clinical need. Patients with these conditions often face delayed diagnoses, repeated testing, and inadequate treatment, leading to increased healthcare costs and reduced quality of life. The whitepaper's emphasis on functional assessment over anatomical imaging aligns with growing recognition that coronary artery disease is not solely about blockages. For the healthcare industry, the findings could accelerate the adoption of non-invasive, cost-effective diagnostic tools in primary care settings, potentially reducing the burden on invasive procedures. For investors, Cardio Diagnostics' focus on building clinical evidence for PrecisionCHD signals a strategic move to capture a share of the cardiovascular diagnostics market, which is increasingly driven by AI and precision medicine.
The full press release can be viewed at https://ibn.fm/N5RnS. For more information about Cardio Diagnostics, visit its client page on BioMedWire. The latest news and updates relating to CDIO are available in the company's newsroom at https://ibn.fm/CDIO.
BioMedWire is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
